Home › Funds › Atle Fund Management AB › TNGX

Atle Fund Management AB position in TNGX

Tango Therapeutics, Inc. · Health Care

Atle Fund Management AB reported holding 184,394 shares of TNGX (Tango Therapeutics, Inc.) in its Q3 2026 13F filing — a position valued at US$4.6M, representing 1.23% of its reported portfolio and ranking #28 among its reported holdings. Atle Fund Management AB has disclosed TNGX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)184.39K sh
Reported value held$4.60M
Portfolio Weight1.23%
First reportedQ1 2026
Last changeReduce
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Atle Fund Management AB's TNGX position evolved

Atle Fund Management AB first disclosed a stake in TNGX in Q1 2026 at 29,915 shares (US$3.6M). The position peaked in Q2 2026 at 198,557 shares, worth US$6.2M. Across 3 filings, Atle Fund Management AB increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 184,394 shares valued at US$4.6M — a reduction of -14,163 shares quarter over quarter.. Notable position changes include a 564% increase in Q2 2026 (shares fell 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 29.91K $3.63M New
Q2 2026 198.56K $6.21M Add
Q3 2026 184.39K $4.60M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TNGX and 13F data

TNGX (Tango Therapeutics, Inc.) is a Health Care company. 85 other funds we track also report a position in TNGX — the largest reported positions include RTW INVESTMENTS, LP (US$434.5M), Farallon Capital Management (US$383.8M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$383.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TNGX

All TNGX fund holders →

FAQ

How long has Atle Fund Management AB held TNGX?

Atle Fund Management AB has disclosed TNGX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Atle Fund Management AB's current position in TNGX?

As of Q3 2026, Atle Fund Management AB holds 184.39K shares of TNGX (Tango Therapeutics, Inc.), valued at $4.60M, representing 1.23% of its reported portfolio and ranking #28.

Has Atle Fund Management AB been buying or selling TNGX?

In the latest 13F filing (Q3 2026), Atle Fund Management AB reduced its position in TNGX. The position peaked in Q2 2026 at 198.56K shares.

Which other funds hold TNGX?

Other major institutional holders of TNGX include RTW INVESTMENTS, LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 85 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.